Drugs / INCB040093
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01905813 | Jun 2013 → Feb 2026 | B-cell neoplasm | Incyte Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02456675 | Jun 2015 → Dec 2016 | Hodgkins lymphoma | Incyte Corporation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-05-27 | Incyte Corporation | Results Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings incyte.com ↗
Phillips, TJ et al; Interim analysis of a Phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients with relapsed or refractory B-cell malignancies. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-05-27 | Incyte Corporation | Incyte Clinical Portfolio to be Featured in 23 Abstract Presentations at the 2015 ASCO and EHA Annual Meetings incyte.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB040093 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01905813 ↗ |
| Action | Inhibit | “INCB040093, a selective PI3Kδ inhibitor” PMID 29695516 ↗ Apr 2018 |
| Route | Oral | “INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.” NCT02456675 ↗ |